Balaxi Pharmaceuticals Limited (NSE:BALAXI)
India
· Delayed Price · Currency is INR 52.00
+0.97 (1.90%)
Jun 6, 2025, 3:29 PM IST
Balaxi Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Operating Revenue | 2,926 | 2,413 | 3,364 | 2,794 | 2,313 | Upgrade
|
| Other Revenue | -37.16 | - | - | - | - | Upgrade
|
| Revenue | 2,888 | 2,413 | 3,364 | 2,794 | 2,313 | Upgrade
|
| Revenue Growth (YoY) | 19.71% | -28.28% | 20.42% | 20.77% | 406.95% | Upgrade
|
| Cost of Revenue | 1,657 | 1,289 | 2,072 | 1,980 | 1,728 | Upgrade
|
| Gross Profit | 1,231 | 1,124 | 1,293 | 814.24 | 585.36 | Upgrade
|
| Selling, General & Admin | 896.45 | 656.74 | 727.32 | 312.19 | 160.86 | Upgrade
|
| Other Operating Expenses | - | -0.11 | -0.26 | -0.3 | -1.75 | Upgrade
|
| Operating Expenses | 915.4 | 677.62 | 744.58 | 317.02 | 162.45 | Upgrade
|
| Operating Income | 316.04 | 446.44 | 548.12 | 497.22 | 422.9 | Upgrade
|
| Interest Expense | -29.35 | -16.77 | -5 | -1.42 | -0.13 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -32.79 | 18.65 | 49.42 | 20.5 | Upgrade
|
| Other Non Operating Income (Expenses) | - | 6.21 | 7.46 | - | -0 | Upgrade
|
| EBT Excluding Unusual Items | 286.7 | 403.09 | 569.22 | 545.22 | 443.29 | Upgrade
|
| Other Unusual Items | - | -382.93 | - | - | - | Upgrade
|
| Pretax Income | 286.7 | 20.15 | 569.22 | 545.22 | 443.29 | Upgrade
|
| Income Tax Expense | 35.99 | 44.02 | 109.6 | 68.65 | 61.92 | Upgrade
|
| Net Income | 250.7 | -23.87 | 459.63 | 476.58 | 381.37 | Upgrade
|
| Net Income to Common | 250.7 | -23.87 | 459.63 | 476.58 | 381.37 | Upgrade
|
| Net Income Growth | - | - | -3.56% | 24.96% | 524.83% | Upgrade
|
| Shares Outstanding (Basic) | 55 | 51 | 50 | 50 | 50 | Upgrade
|
| Shares Outstanding (Diluted) | 55 | 51 | 51 | 50 | 50 | Upgrade
|
| Shares Change (YoY) | 7.29% | 1.69% | 1.23% | - | 32.96% | Upgrade
|
| EPS (Basic) | 4.54 | -0.46 | 9.16 | 9.53 | 7.63 | Upgrade
|
| EPS (Diluted) | 4.54 | -0.46 | 9.08 | 9.53 | 7.63 | Upgrade
|
| EPS Growth | - | - | -4.74% | 24.96% | 369.94% | Upgrade
|
| Free Cash Flow | -561.23 | 41.74 | -69.83 | 288.23 | -12.74 | Upgrade
|
| Free Cash Flow Per Share | -10.16 | 0.81 | -1.38 | 5.76 | -0.26 | Upgrade
|
| Dividend Per Share | - | - | - | 0.100 | - | Upgrade
|
| Gross Margin | 42.63% | 46.58% | 38.42% | 29.14% | 25.30% | Upgrade
|
| Operating Margin | 10.94% | 18.50% | 16.29% | 17.80% | 18.28% | Upgrade
|
| Profit Margin | 8.68% | -0.99% | 13.66% | 17.06% | 16.49% | Upgrade
|
| Free Cash Flow Margin | -19.43% | 1.73% | -2.08% | 10.32% | -0.55% | Upgrade
|
| EBITDA | 334.99 | 465.57 | 565.64 | 502.34 | 425.88 | Upgrade
|
| EBITDA Margin | 11.60% | 19.30% | 16.81% | 17.98% | 18.41% | Upgrade
|
| D&A For EBITDA | 18.95 | 19.14 | 17.53 | 5.12 | 2.98 | Upgrade
|
| EBIT | 316.04 | 446.44 | 548.12 | 497.22 | 422.9 | Upgrade
|
| EBIT Margin | 10.94% | 18.50% | 16.29% | 17.80% | 18.28% | Upgrade
|
| Effective Tax Rate | 12.55% | 218.44% | 19.25% | 12.59% | 13.97% | Upgrade
|
| Revenue as Reported | 2,888 | 2,386 | 3,391 | 2,844 | 2,336 | Upgrade
|
| Advertising Expenses | - | 6.55 | 8.41 | 10.21 | 1.02 | Upgrade
|
Updated Feb 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.